Daré Bioscience, Inc. (DARE)Healthcare | Biotechnology | San Diego, United States | NasdaqCM
2.53 USD
-0.34
(-11.784%) ⇩
(April 21, 2026, 2:06 p.m.
EDT)
Short-term: ★☆☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 11:28 p.m. EDT
Bearish momentum driven by recent earnings misses and deteriorating fundamentals; optimal for put strategies due to forecasted -2.72% price prediction and unprofitable cash flow. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.182933 |
| AutoARIMA | 0.182936 |
| MSTL | 0.185442 |
| AutoTheta | 0.213676 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 35% |
| H-stat | 1.77 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 3.88 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 93.435 |
| Revenue per Share | 0.092 |
| Market Cap | 36,861,748 |
| Forward P/E | 4.33 |
| Beta | 0.90 |
| Website | https://darebioscience.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.03367001 |
| Address1 | 3,655 Nobel Drive |
| Address2 | Suite 260 |
| All Time High | 1,304.4 |
| All Time Low | 1.27 |
| Ask | 3.07 |
| Ask Size | 2 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 1,458,280 |
| Average Daily Volume3 Month | 313,285 |
| Average Volume | 313,285 |
| Average Volume10Days | 1,458,280 |
| Beta | 0.9 |
| Bid | 2.1 |
| Bid Size | 2 |
| Book Value | 0.196 |
| City | San Diego |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.5318 |
| Current Ratio | 1.143 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 2.95 |
| Day Low | 2.4 |
| Debt To Equity | 93.435 |
| Display Name | Daré Bioscience |
| Dividend Date | 1,500,508,800 |
| Earnings Call Timestamp End | 1,774,557,000 |
| Earnings Call Timestamp Start | 1,774,557,000 |
| Earnings Timestamp | 1,774,555,200 |
| Earnings Timestamp End | 1,778,616,000 |
| Earnings Timestamp Start | 1,778,616,000 |
| Ebitda | -11,917,848 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -1.656 |
| Enterprise To Revenue | 19.152 |
| Enterprise Value | 19,730,434 |
| Eps Current Year | -1.21 |
| Eps Forward | 0.585 |
| Eps Trailing Twelve Months | -1.2 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.6993 |
| Fifty Day Average Change | 0.8325 |
| Fifty Day Average Change Percent | 0.4899076 |
| Fifty Two Week Change Percent | -3.3670008 |
| Fifty Two Week High | 9.19 |
| Fifty Two Week High Change | -6.6581993 |
| Fifty Two Week High Change Percent | -0.7245048 |
| Fifty Two Week Low | 1.27 |
| Fifty Two Week Low Change | 1.2618 |
| Fifty Two Week Low Change Percent | 0.9935434 |
| Fifty Two Week Range | 1.27 - 9.19 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,397,136,600,000 |
| Float Shares | 13,311,461 |
| Forward Eps | 0.585 |
| Forward P E | 4.3278637 |
| Free Cashflow | -4,802,669 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 21 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.71287 |
| Gross Profits | 734,394 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.085719995 |
| Held Percent Institutions | 0.084350005 |
| Implied Shares Outstanding | 14,559,502 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,719,792,000 |
| Last Split Factor | 1:12 |
| Long Business Summary | Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder; DARE-HRT1 to treat vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of dyspareunia or pain during sexual intercourse; and DARE-HPV, a fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert to treat genital human papillomavirus (HPV) infection, cervical intraepithelial neoplasia, and other HPV-related pathologies. In addition, the company develops DARE-PDM1, a hydrogel formulation of diclofenac for vaginal administration to treat primary dysmenorrhea; DARE-204 and DARE-214, injectable formulations of etonogestrel that provides contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. Further, it develops DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design controlled contraceptive option; DARE-RH1, an approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein; DARE-LBT, a vaginal thermosetting gel formulation for the delivery of live biotherapeutics; and DARE-GML, which delivers antimicrobial glycerol monolaurate intravaginally. Daré Bioscience, Inc. was founded in 2015 and is headquartered in San Diego, California. |
| Long Name | Daré Bioscience, Inc. |
| Market | us_market |
| Market Cap | 36,861,748 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_423979060 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -13,399,274 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 41,931,365 |
| Number Of Analyst Opinions | 3 |
| Open | 2.85 |
| Operating Cashflow | -9,885,870 |
| Operating Margins | -1.43724 |
| Payout Ratio | 0.0 |
| Phone | 858 926 7655 |
| Previous Close | 2.87 |
| Price Eps Current Year | -2.0923967 |
| Price Hint | 4 |
| Price To Book | 12.917348 |
| Price To Sales Trailing12 Months | 35.7814 |
| Profit Margins | 0.0 |
| Quick Ratio | 1.067 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.33333 |
| Region | US |
| Regular Market Change | -0.33819985 |
| Regular Market Change Percent | -11.783967 |
| Regular Market Day High | 2.95 |
| Regular Market Day Low | 2.4 |
| Regular Market Day Range | 2.4 - 2.95 |
| Regular Market Open | 2.85 |
| Regular Market Previous Close | 2.87 |
| Regular Market Price | 2.5318 |
| Regular Market Time | 1,776,794,788 |
| Regular Market Volume | 1,012,023 |
| Return On Assets | -0.3104 |
| Revenue Per Share | 0.092 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 14,559,502 |
| Shares Percent Shares Out | 0.0145000005 |
| Shares Short | 211,491 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 290,470 |
| Short Name | Dare Bioscience, Inc. |
| Short Percent Of Float | 0.0146 |
| Short Ratio | 2.11 |
| Source Interval | 15 |
| State | CA |
| Symbol | DARE |
| Target High Price | 12.0 |
| Target Low Price | 8.0 |
| Target Mean Price | 9.66667 |
| Target Median Price | 9.0 |
| Total Cash | 24,711,356 |
| Total Cash Per Share | 1.697 |
| Total Debt | 2,656,019 |
| Total Revenue | 1,030,193 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.2 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.990675 |
| Two Hundred Day Average Change | 0.54112506 |
| Two Hundred Day Average Change Percent | 0.27182993 |
| Type Disp | Equity |
| Volume | 1,012,023 |
| Website | https://darebioscience.com |
| Zip | 92,122 |